COMPANY UPDATES
19
Sep
2016
Strategic partnership with Stem Cell Theranostics in joint CIRM grant application

Novoheart has entered into a strategic partnership with Stanford biotech startup Stem Cell Theranostics (SCT), based in the Bay Area, for a joint grant application to the California Institute of Regenerative Medicine (CIRM).

SCT is a discovery stage biotechnology company with an exclusive partnership with Stanford University Cardiovascular Institute, with strengths in genetic and drug-induced heart disease. SCT’s unique access to patient samples and expertise in the stem cell space, combined with Novoheart’s world-class cardiac tissue engineering capabilities, yields a powerful platform for studying heart diseases.

For more information on SCT, please refer to the official website.

 

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!